VIRTUS Safety and Efficacy of the Veniti Vici™ Venous Stent System (Veniti, Inc.) When Used to Treat Clinically Significant Chronic Non-malignant Obstruction of the Iliofemoral Venous Segment
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 200
- 试验地点
- 24
- 主要终点
- Number of Participants With Major Adverse Events (MAE)
研究概览
简要总结
This is a prospective, multi-center, single arm, non-randomized study to define safety and efficacy of the Veniti Vici™ Venous Stent System in relation to pre-defined Objective Performance goals. A maximum of 200 patients at up to 45 centers worldwide will be enrolled. Thirty (30) feasibility patients will be enrolled at approximately 7-10 centers and 170 pivotal patients will be enrolled at approximately 45 centers worldwide. The follow-up period is 36 months.
详细描述
The objective of this prospective study is to assess the safety and efficacy of the Veniti Vici™ Venous Stent System in achieving patency of the target venous lesion in patients who present with clinically significant chronic non-malignant obstruction of the iliofemoral venous outflow tract.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Sequential
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Pre-Procedure Criteria:
- •Age ≥ 18 years
- •Willing and capable of complying with all follow-up evaluations at the specified times
- •Able and willing to provide written informed consent prior to study-specific procedures
- •Presence of unilateral, clinically significant, chronic non-malignant obstruction of the common femoral vein, external iliac vein, common iliac vein, or any combination thereof, defined as a ≥50% reduction in target vessel lumen diameter (to be measured by venogram during procedure)
- •Clinically significant venous obstruction defined as meeting at least one of the following clinical indicators:
- •Clinical severity class of CEAP classification ≥3
- •VCSS Pain Score ≥2
- •Negative pregnancy test in females of child-bearing potential
- •Intention to stent the target lesion only with the Veniti Vici Venous Stent
排除标准
- •Pre-Procedure Criteria:
- •Presence or history of clinically significant pulmonary emboli within 6 months prior to enrollment.
- •Venous obstruction that extends into the inferior vena cava (IVC)
- •Contralateral disease of the common femoral vein, external iliac vein, common iliac vein, or any combination thereof with planned treatment within 30 days after subject enrollment
- •Life expectancy <12 months
- •Female of childbearing potential who is pregnant or plans to become pregnant during the duration of the clinical study
- •Uncontrolled or active coagulopathy OR known, uncorrectable bleeding diathesis with the following definitions:
- •Uncorrected INR ≥2.0 or aPTT ≥1.5 X normal local lab value
- •Platelet count <80,000
- •Uncorrected hemoglobin of ≤ 9 g/dL
- •Patients with an estimated glomerular filtration rate (eGFR) <30 mL/min. In patients with diabetes mellitus, eGFR <45 mL/min.
- •Known hypersensitivity to nickel or titanium
- •Contrast agent allergy that cannot be managed adequately with pre-medication
- •Intended concurrent thrombolysis or thrombectomy procedure OR intended or planned (within 30 days) adjuvant procedure such as creation of temporary arteriovenous fistula, placement of IVC filter, endovenectomy or saphenous vein ablation
- •Current or recent (within 30 days) active participation in another drug or device clinical trial (Participation in observational studies is acceptable.)
- •Patient judged to be a poor candidate by the primary investigator
- •Patients who have had any prior surgical or endovascular intervention of the target vessel [Note: Patients who have had catheter-directed or mechanical thrombolysis in the target vessel for DVT at least 3 month (90 days) prior to the VIRTUS index procedure may be included in the trial.]
- •Exclusion Criteria - Intra-Procedural Criteria:
- •Patients in whom the lesions cannot be traversed with a guide wire.
- •Patients where the obstruction extends into the inferior vena cava or below the level of the lesser trochanter.
- •Patients whose vein diameters are not within limits stated in current Instructions for Use as determined by venogram.
- •Patients who do not meet the venogram binary stenosis definition, as determined by the treating physician.
研究组 & 干预措施
VICI Stent Implantation - Feasibility
Percutaneous stent placement in the common femoral vein, external iliac vein and/or common iliac vein Veniti Vici™ Venous Stent System
干预措施: Veniti Vici™ Venous Stent System (Device)
VICI Stent Implantation - Pivotal
Percutaneous stent placement in the common femoral vein, external iliac vein and/or common iliac vein Veniti Vici™ Venous Stent System
干预措施: Veniti Vici™ Venous Stent System (Device)
结局指标
主要结局
Number of Participants With Major Adverse Events (MAE)
时间窗: 30 days
The primary safety endpoint for this study will be a composite endpoint of any major adverse event (MAE) within 30 days, as adjudicated by a Clinical Events Committee.
Percentage of Participants That Demonstrated Primary Patency
时间窗: 12 months post-intervention
The primary effectiveness endpoint is the primary patency rate at 12 months post-intervention, defined as freedom from occlusion by thrombosis, freedom from surgical or endovascular intervention on target vessel which are found to have re-stenosis or stent occlusion to maintain patency, and freedom from in-stent stenosis more than 50% by venogram.
次要结局
- Number of Participants With Improvement in Venous Clinical Severity Score (VCSS)(12 months post-intervention)